These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 6775855)

  • 1. Whole body aluminium in chronic renal failure and dialysis encephalopathy.
    Williams ED; Elliott HL; Boddy K; Haywood JK; Henderson IS; Harvey I; Kennedy AC
    Clin Nephrol; 1980 Oct; 14(4):198-200. PubMed ID: 6775855
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aluminium studies in dialysis encephalopathy.
    Elliott HL; Macdougall AI
    Proc Eur Dial Transplant Assoc; 1978; 15():157-63. PubMed ID: 740662
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aluminium encephalopathy: a potential risk of aluminium gels in children with chronic renal failure.
    Pillion G; Loirat C; Blum C; Poisson M; Bacri JL; Broyer M; Mathieu H
    Int J Pediatr Nephrol; 1981 Mar; 2(1):29-32. PubMed ID: 7333766
    [No Abstract]   [Full Text] [Related]  

  • 4. [Prolonged and reversible encephalopathy in a chronic haemodialysis patient. Probable responsibility of aluminium salts (author's transl)].
    Buge A; Poisson M; Masson S; Bleibel JM; Lafforgue B; Raymond P; Jaudon MC
    Nouv Presse Med; 1978 Jun; 7(23):2053-9. PubMed ID: 673773
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lanthanum: new drug. Hyperphosphataemia in dialysis patients: more potential problems than benefits.
    Prescrire Int; 2007 Apr; 16(88):47-50. PubMed ID: 17458039
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evidence for aluminium accumulation in renal failure.
    Marsden SN; Parkinson IS; Ward MK; Ellis HA; Kerr DN
    Proc Eur Dial Transplant Assoc; 1979; 16():588-96. PubMed ID: 549003
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aluminum and chronic renal failure: sources, absorption, transport, and toxicity.
    Wills MR; Savory J
    Crit Rev Clin Lab Sci; 1989; 27(1):59-107. PubMed ID: 2647415
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Exacerbation of aluminium encephalopathy after treatment with desferrioxamine.
    Lillevang ST; Pedersen FB
    Nephrol Dial Transplant; 1989; 4(7):676. PubMed ID: 2510071
    [No Abstract]   [Full Text] [Related]  

  • 9. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dialysis encephalopathy: precipitating factors and improvement in prognosis.
    Platts MM; Anastassiades E
    Clin Nephrol; 1981 May; 15(5):223-8. PubMed ID: 7249421
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Progressive myoclonic encephalopathy in dialysis patients: presence of high concentrations of aluminium in the lysosomes of the cerebral cells (author's transl)].
    Galle P; Chatel M; Berry JP; Menault F
    Nouv Presse Med; 1979 Dec; 8(50):4091-4. PubMed ID: 530824
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [A long-term organic brain syndrome and brain stem symptoms in an undiagnosed dialysis-associated encephalopathy].
    Reusche E; Gerke P; Krüger S; Rohwer J; Lindner B; Rob PM
    Dtsch Med Wochenschr; 1999 Feb; 124(7):176-81. PubMed ID: 10093576
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Progressive myoclonic encephalopathy in dialysis patients. The role of the water used for haemodialysis (author's transl)].
    Cartier F; Allain P; Gary J; Chatel M; Menault F; Pecker S
    Nouv Presse Med; 1978 Jan; 7(2):97-102. PubMed ID: 652514
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The natural history of dialysis encephalopathy (author's transl)].
    Pogglitsch H; Wawschinek O; Holzer H; Petek W; Ladurner G; Katschnig H; Korthals C
    Acta Med Austriaca; 1980; 7(3):71-6. PubMed ID: 7223340
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Determination of the plasma aluminum concentration of hemodialysis patients].
    Kuleva V; Petrov I; Antonov S; Kiriakov Z
    Vutr Boles; 1984; 23(2):51-5. PubMed ID: 6741112
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Two forerunners of the encephalopathy of hemodialysed patients : osteomalacic osteodystrophy and electroencephalographic alterations. Influence of the aluminium concentration in the dialysis fluid (author's transl)].
    Vecchierini-Blineau MF; Thébaud HE; Brochard D; Coville P
    Nephrologie; 1980; 1(1):29-32. PubMed ID: 7301017
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of conjunctival and corneal calcification with vascular calcification in dialysis patients.
    Seyahi N; Altiparmak MR; Kahveci A; Yetik H; Kanberoglu K; Serdengecti K; Ataman R; Erek E
    Am J Kidney Dis; 2005 Mar; 45(3):550-6. PubMed ID: 15754277
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Dialysis encephalopathy and aluminum poisoning? Correlated clinical, pathologic-anatomic and spectrometric findings].
    Weiller C; Spiegel P; Van de Vijver F
    Nervenarzt; 1986 Aug; 57(8):461-4. PubMed ID: 3092120
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hypochromic anaemia in chronic renal failure--role of aluminium.
    Varma PP; Kumar R; Prasher PK; Roy ND
    J Assoc Physicians India; 1999 Jul; 47(7):690-3. PubMed ID: 10778588
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardiac and vascular adaptation in pediatric patients with chronic kidney disease: role of calcium-phosphorus metabolism.
    Mitsnefes MM; Kimball TR; Kartal J; Witt SA; Glascock BJ; Khoury PR; Daniels SR
    J Am Soc Nephrol; 2005 Sep; 16(9):2796-803. PubMed ID: 16049067
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.